[1] Ruhlmann J, Schomburg A, Bender H, et al. Fluorode oxyglucose whole-body positron emission tomography in colorectal cancer patients studied in rourine daily practice[J].Dis Colon Rectum, 1997, 40:1195-1204.
[2] Hung GU, Shiau YC, Tsai SC, et al. Value of 18F-FDGPET in the evaluation of recurrent colorectal cancer[J]. Anticancer Res, 2001, 21(2B):1375-1378.
[3] Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer[J]. Ann Surg, 1998,27:319-323.
[4] Zhuang H, Sinha P, Pourdehnad M, et al. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver[J].Nucl Med Commun, 2000, 21(9):793-798.
[5] Fong Y, Choheb AM, Fortner JG, et al. Liver resection for colorectal metastases[J]. J Clin Oncol, 2001, 15:938-946.
[6] Jarnagin WR, Fong Y, Ky A, et al. Liver resection for metastatic colorectal cancer:. Assessing the risk of occult irresectabale disease[J]. J Am Coll Surg, 1999, 188:33-42.
[7] Fong Y, Saldinger PF, Akhurst T, et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases[J]. Am J Surg, 1999, 178:282-287.
[8] Strasberg SM, Dehdashti F, Siegel BA, et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma:A prospective databases study[J]. Ann Surg, 2001, 233:293-299.
[9] Brennan MF. PET scanning in malignancy:Infant, adolescent or mature citizen[J]. Ann Surg, 2001, 233:320-321.
[10] Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer[J]. Ann Surg, 2001, 233:310-319.
[11] Meta J, Seltzer M, Schiepers C, et al. Impact of 18F-FDG PET on managing patients with colorectal cancer:The referring physician's perspective[J]. J Nucl Med, 2001, 42:586-590.
[12] Darius C, Desai MD, Emanuel E, et al. Positron emission tomography affects surgical management in recurrent colorectal cancer patients[J]. Ann Surg, 2003, 10:59-64.
[13] Whiteford MH, Whitefor HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocareinoma of the colon and rectum[J].Dis Colon Rectum, 2000, 43:759-770.
[14] Guillem JG, Puig-La CJ Jr, Akhursf T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18F-fluorodeoxyglucose positron emission tomography[J]. Dis Colon Rectum,2000, 43:18-24.
[15] Bender H, Bangard N, Metten N, et al. Possible role of FDG PET the early predication of therapy outcome in liver metastases of colorectal cancer[J]. Hybridoma, 1999, 18(1):87-91.